229,704 Shares in Celcuity, Inc. $CELC Bought by Jennison Associates LLC

Jennison Associates LLC bought a new position in shares of Celcuity, Inc. (NASDAQ:CELC) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 229,704 shares of the company’s stock, valued at approximately $22,911,000.

Other institutional investors have also added to or reduced their stakes in the company. Ogorek Anthony Joseph NY ADV acquired a new position in Celcuity during the third quarter worth $27,000. US Bancorp DE increased its holdings in shares of Celcuity by 25.4% in the third quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after purchasing an additional 143 shares during the last quarter. NBC Securities Inc. acquired a new position in shares of Celcuity in the fourth quarter valued at $99,000. Versant Capital Management Inc increased its holdings in shares of Celcuity by 611.2% in the third quarter. Versant Capital Management Inc now owns 1,593 shares of the company’s stock valued at $79,000 after purchasing an additional 1,369 shares during the last quarter. Finally, Everhart Financial Group Inc. acquired a new position in shares of Celcuity in the fourth quarter valued at $209,000. 63.33% of the stock is currently owned by institutional investors and hedge funds.

Celcuity Trading Up 3.5%

CELC stock opened at $125.65 on Friday. The company has a debt-to-equity ratio of 3.20, a quick ratio of 10.55 and a current ratio of 10.55. The company’s 50-day simple moving average is $114.53 and its 200 day simple moving average is $101.86. Celcuity, Inc. has a 52 week low of $9.51 and a 52 week high of $129.09. The company has a market capitalization of $6.07 billion, a PE ratio of -33.15 and a beta of 0.41.

Celcuity (NASDAQ:CELC) last released its quarterly earnings results on Wednesday, March 25th. The company reported ($0.97) EPS for the quarter, beating the consensus estimate of ($1.06) by $0.09. As a group, sell-side analysts anticipate that Celcuity, Inc. will post -3.97 earnings per share for the current year.

Insider Activity at Celcuity

In related news, Director Richard E. Buller sold 3,000 shares of the company’s stock in a transaction dated Tuesday, March 31st. The shares were sold at an average price of $110.27, for a total value of $330,810.00. Following the transaction, the director directly owned 6,760 shares in the company, valued at approximately $745,425.20. This represents a 30.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 13.33% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on CELC shares. Citizens Jmp started coverage on shares of Celcuity in a report on Monday, April 27th. They issued a “market outperform” rating and a $150.00 price objective on the stock. Stifel Nicolaus upped their price objective on shares of Celcuity from $115.00 to $125.00 and gave the company a “buy” rating in a report on Thursday, March 26th. Needham & Company LLC reiterated a “buy” rating and issued a $122.00 price objective on shares of Celcuity in a report on Thursday, March 26th. Citigroup started coverage on shares of Celcuity in a report on Monday. They issued an “outperform” rating on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Celcuity in a report on Monday, April 20th. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $114.33.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.